Quick Answer
NEUROONE MEDICAL TECHNOLOGIES Corp reported Total Revenue of $9.10 million for fiscal year 2025.
NEUROONE MEDICAL TECHNOLOGIES Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.10M +163.5% |
$3.45M +76.9% |
$1.95M +1040.7% |
$171.2K -3.9% |
$178.1K | — |
| Net Income | -$3.61M +70.7% |
-$12.32M -3.9% |
-$11.86M -18.6% |
-$10.00M -0.5% |
-$9.95M +27.1% |
-$13.64M -101.1% |
| Diluted EPS | -$0.09 +80.4% |
-$0.46 +29.2% |
-$0.65 -3.2% |
-$0.63 +32.3% |
-$0.93 | — |
| Total Assets | $10.79M +100.9% |
$5.37M -33.7% |
$8.10M -36.9% |
$12.82M +61.5% |
$7.94M +66.8% |
$4.76M +793.7% |
| Cash and Equivalents | $6.57M +350.0% |
$1.46M -72.6% |
$5.32M -34.8% |
$8.16M +18.2% |
$6.90M +71.0% |
$4.04M +1448.0% |
| Stockholders Equity | $7.07M +760.4% |
$822.0K -86.8% |
$6.25M -34.9% |
$9.60M +46.5% |
$6.55M +217.2% |
$2.07M +267.0% |
| R&D Expense | $4.98M -1.6% |
$5.07M -27.0% |
$6.94M +40.8% |
$4.93M +25.6% |
$3.93M +89.1% |
$2.08M +35.7% |
| Operating Income | -$4.23M +64.4% |
-$11.89M +0.6% |
-$11.96M -19.2% |
-$10.03M +1.8% |
-$10.22M -108.4% |
-$4.90M +15.7% |
| Gross Profit | $5.14M +376.2% |
$1.08M +136.5% |
$456.5K +744.9% |
-$70.8K +27.6% |
-$97.7K | — |
| Shares Outstanding | 50.01M +62.3% |
30.82M +28.8% |
23.93M +47.6% |
16.22M +35.0% |
12.01M +62.4% |
7.39M -45.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $2.89M | -11.7% | +70.6% |
| Net Income | December 31, 2025 | -$1.44M | -180.5% | +4.2% |
| Diluted EPS | December 31, 2025 | -$0.03 | -150.0% | +0.0% |
| Total Assets | December 31, 2025 | $8.58M | +32.1% | -20.5% |
| Cash and Equivalents | December 31, 2025 | $3.56M | +214.0% | -45.8% |
| Stockholders Equity | December 31, 2025 | $6.40M | +118.1% | -9.5% |
| R&D Expense | December 31, 2025 | $1.39M | +18.6% | +17.5% |
| Operating Income | December 31, 2025 | -$1.71M | -199.8% | +9.5% |
| Gross Profit | December 31, 2025 | $1.57M | -18.6% | +71.4% |
| Shares Outstanding | December 31, 2025 | 50.41M | +63.5% | +0.8% |
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Total Revenue of $9.10 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +163.5% in Total Revenue compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Net Income of -$3.61 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +70.7% in Net Income compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Diluted EPS of $0.09 per share (loss) for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +80.4% in Diluted EPS compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Total Assets of $10.79 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +100.9% in Total Assets compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Cash and Equivalents of $6.57 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +350.0% in Cash and Equivalents compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Stockholders Equity of $7.07 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +760.4% in Stockholders Equity compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported R&D Expense of $4.98 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed a decrease of -1.6% in R&D Expense compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Operating Income of -$4.23 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +64.4% in Operating Income compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Gross Profit of $5.14 million for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +376.2% in Gross Profit compared to the prior fiscal year.
- NEUROONE MEDICAL TECHNOLOGIES Corp reported Shares Outstanding of 50.01 million shares for fiscal year 2025.
- NEUROONE MEDICAL TECHNOLOGIES Corp showed an increase of +62.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: